[BBH] Merrill Lynch Biotech HOLDRS ETF

Overview

Type of security: Fund

Tags: Biotech, Country, Equity, ETF, Health, Health care, Index Based, Not Inversed, Stocks, U.S., Unleveraged

The data is delayed by 15 minutes.

 

Price: 109.25 Change: 1.84 (1.71%)
Ext. hours: Change: 0 (0%)

chart BBH

Refresh chart

Strongest Trends Summary For BBH

BBH is in the long-term up 281% above S&P in 25 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

See how to gain 20% in 14 sec with TrendsInvesting

Technical Data
High 52 week135.35 Low 52 week103.76 Last close129.68 Last change1.23%
RSI56.83 Average true range1.58 Beta0.91 Volume78.26 K
Simple moving average 20 days2.23% Simple moving average 50 days6.87% Simple moving average 200 days4.72%
Performance Data
Performance Week0.36% Performance Month3.48% Performance Quart11.86% Performance Half-0.79%
Performance Year6.86% Performance Year-to-date17.12% Volatility daily1.04% Volatility weekly2.33%
Volatility monthly4.77% Volatility yearly16.51% Relative Volume263.53% Average Volume27.94 K
New High New Low
Funds Characteristics
30-day SEC yield-0.11 Average market capitalization Average weighted market capitalization46.38 B Forward P/E
Gross expense ratio0.41% Index dividend yield Median market cap Number of holdings25
Price to Book Value 6.53 Price to Earnings37.07 Total expense ratio Total net assets
Weighted market capitalization

Info

Characteristics:
NAME VALUE
30 Day Sec Yield-0,11
P/E Ratio37,07
P/Bv Ratio6,53
Gross Expense Ratio0,41
Average Weighted Market Capitalization46378,7
Number Of Holdings25
Countries:
NAME VALUE
United States96,2
Netherlands3,8
Company Size:
NAME VALUE
Large 5.0 B85,5
Medium 1.0 - 5.0 B14,5
Holdings:
NAME VALUE
Gilead Sciences, Inc. Gild Us13,8
Amgen Inc. Amgn Us10,83
Biogen Idec Inc. Biib Us9,33
Celgene Corporation Celg Us9,01
Alexion Pharmaceuticals, Inc. Alxn Us5,2
Regeneron Pharmaceuticals, Inc. Regn Us5,03
Alkermes Plc Alks Us4,91
Illumina, Inc. Ilmn Us4,68
Vertex Pharmaceuticals Incorporated Vrtx Us4,53
Qiagen Nv Qgen Us3,77
Biomarin Pharmaceutical Inc. Bmrn Us3,51
Incyte Corporation Incy Us3,47
Medivation, Inc. Mdvn Us2,81
Isis Pharmaceuticals, Inc. Isis Us2,55
Pharmacyclics, Inc. Pcyc Us2,38

News

2019-02-25 10:15:03 | Top-Ranked ETF Winners in Dow's Longest Rally in 24 Years

2019-02-14 13:00:06 | Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

2019-01-24 13:00:06 | What's Behind the Biotech ETF Rally to Start 2019?

2019-01-24 11:34:40 | Biotech ETFS: How To Pick Biotech Stock Winners And Avoid Volatility In 2019

2019-01-04 10:01:03 | Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

2018-11-16 17:52:00 | VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs

2018-10-30 15:20:53 | Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

2018-10-30 11:05:11 | Recommendations for Shire as of October 30

2018-10-26 11:10:02 | What Analysts Recommend for Incyte ahead of Q3 Earnings

2018-10-25 12:35:09 | Amgen: Expect Nearly Flat Revenues in Q3

2018-10-24 13:25:02 | Allergan’s Q3 2018 Estimates: Revenue Decline Expected

2018-10-19 14:25:01 | Biogen: Analysts’ Recommendations on October 19

2018-10-17 11:48:00 | VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry

2018-10-09 07:32:17 | Analysts Are Mostly Positive on Neurocrine Biosciences

2018-10-04 09:01:49 | Allergan’s Stock Performance and Estimates for Q3 2018

2018-10-03 09:02:46 | Ionis Pharmaceuticals’ Valuations on September 28

2018-09-25 09:03:09 | Allergan’s Developments in September

2018-09-21 07:32:38 | Estimates and Recommendations for Shire on September 19

2018-09-06 15:35:02 | Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

2018-08-22 10:20:08 | A Look at Incyte’s Valuation on August 22

2018-08-20 15:40:02 | Examining Amgen’s Revenue Trend in Q2 2018

2018-08-17 09:35:10 | Considering Allergan’s Q2 2018 Revenue Trend

2018-08-08 13:15:02 | What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

2018-08-03 11:06:39 | Bluebird Bio Misses Analysts’ Estimates in Q2 2018

2018-08-02 12:55:00 | Adding Biotech ETFs to Your Portfolio

2018-07-31 15:25:12 | What Analysts Recommend for Bluebird Bio Stock

2018-07-31 15:24:00 | Shire’s Q2 2018 Earnings Beat Analyst Estimates

2018-07-06 13:50:51 | Biotech ETFs Climb on Biogen’s Promising Clinical Trial

2018-06-27 12:15:04 | Top-Ranked Sector ETFs to Buy for Q3

2018-05-24 17:45:02 | What Drove Ionis’s Revenue in Q1

2018-05-18 08:08:52 | BlueBird Bio Stock Jumps over 6% on May 17

2018-05-04 13:57:22 | Allergan Reports Growth in 1Q18 Revenues

2018-04-27 11:05:33 | Allergan’s 1Q18 Earnings: Analysts’ Estimates

2018-03-26 08:12:28 | What’s Ionis Pharmaceuticals’ Valuation in March 2018?

2018-03-22 17:38:56 | A Look at Incyte’s Valuation in March 2018

2018-03-19 16:15:00 | The 4 Top Biotech ETFs

2018-03-08 07:31:25 | Gilead Sciences: Analysts’ Estimates after 4Q17

2018-01-25 09:55:00 | 4 ETFs Set to Surge Amid Q4 Earnings

2018-01-10 17:40:02 | A Look at Ionis’s 3Q17 Revenue Stream

2018-01-09 11:55:03 | How Was Incyte’s Revenue Stream in 3Q17?

2017-12-15 18:56:00 | VanEck Announces Yearend Distributions for VanEck Vectors Equity ETFs

2017-11-22 17:30:00 | VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs

2017-10-03 06:31:00 | Investors getting back into M&A : York Capital co-CEO

2017-09-18 12:36:26 | Benefitting from IBB’s Lower Expense Ratio

2017-09-11 12:05:56 | How Gilead’s HIV and HBV Portfolios Performed in 2Q17

2017-09-06 09:30:00 | The Summer Of Biotech Isn't Over Yet

2017-08-30 18:50:00 | ETF Topper: Biotechnology Stocks Continue to Show Strength

2017-08-24 10:36:07 | How Akcea Therapeutics’ Volanesorsen Performed in 2Q17

2017-08-22 14:05:53 | Understanding Incyte’s 2Q17 Revenue Stream

2017-08-21 15:11:26 | What’s Allergan’s Valuation after 2Q17 Earnings?